Current Treatment Options in Oncology最新文献

Fertility Sparing Medical Management Options in Gynecologic Cancers.

IF 3.8 2区医学

Current Treatment Options in Oncology Pub Date : 2025-02-19 DOI: 10.1007/s11864-025-01299-4

Ana Kouri, Janelle P Darby

{"title":"Fertility Sparing Medical Management Options in Gynecologic Cancers.","authors":"Ana Kouri, Janelle P Darby","doi":"10.1007/s11864-025-01299-4","DOIUrl":"https://doi.org/10.1007/s11864-025-01299-4","url":null,"abstract":"Opinion statement: There is an increasing use of medical management for gynecologic cancers given the rise in neoadjuvant therapies, delayed childbearing, and use of assisted reproductive technology. Chemotherapy, albeit broadly used in most gynecologic cancers, lacks long term data with respect to its associated gonadotoxicity and potential adverse pregnancy outcomes. Immunotherapy and other targeted therapies that have demonstrated promising responses in other tumor types are increasingly being studied in gynecologic malignancies. These therapies may offer opportunities for enhanced treatment response in an effort to minimize more toxic, invasive, or surgical management approaches that could have significant negative implications on fertility. Given that some of these therapies do not represent the standard of care and currently only exist in the experimental setting, detailed counseling and careful selection of patients for fertility sparing treatment remains critical. It is reasonable for patients with early stage, low-risk endometrial cancers to attempt conservative management while establishing clear treatment objectives. Early involvement of fertility specialists is necessary in order to optimize these patients' pregnancy goals. An emphasis on lifestyle changes and in particular weight loss should also be discussed with these patients. Neoadjuvant chemotherapy followed by fertility sparing surgery in cervix cancer patients with low-risk, small tumors shows promising results that suggest this can be a safe treatment option. Patients with advanced stage disease of any primary tumor or aggressive histology such as in many cases of ovarian cancer are not appropriate candidates for prioritization of fertility sparing treatment options. Ongoing and future studies will help to better identify appropriate patients and maximize medical management options in early-stage gynecologic cancers.","PeriodicalId":50600,"journal":{"name":"Current Treatment Options in Oncology","volume":" ","pages":""},"PeriodicalIF":3.8,"publicationDate":"2025-02-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143450349","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Correction to: Metastatic Hormone-Sensitive Prostate Cancer in the Era of Doublet and Triplet Therapy.

IF 3.8 2区医学

Current Treatment Options in Oncology Pub Date : 2025-02-01 DOI: 10.1007/s11864-025-01294-9

Anthony V Serritella, Maha Hussain

引用次数: 0

Advancements in Diagnosis and Treatment of Cardiac Sarcomas: A Comprehensive Review.

IF 3.8 2区医学

Current Treatment Options in Oncology Pub Date : 2025-02-01 Epub Date: 2025-01-31 DOI: 10.1007/s11864-024-01287-0

Xuezhe Wang, Xinchi Luan, Wenwen Yin, Yilin Wang, Xiaoxuan Li, Ruolan Chen, Guoliang Zhang, Ruizhe Zhao, Xue Dong, Zhishang Zhang, Yuchen Fan, Zhaodong Li, Xianming Chu, Shuang Wang

{"title":"Advancements in Diagnosis and Treatment of Cardiac Sarcomas: A Comprehensive Review.","authors":"Xuezhe Wang, Xinchi Luan, Wenwen Yin, Yilin Wang, Xiaoxuan Li, Ruolan Chen, Guoliang Zhang, Ruizhe Zhao, Xue Dong, Zhishang Zhang, Yuchen Fan, Zhaodong Li, Xianming Chu, Shuang Wang","doi":"10.1007/s11864-024-01287-0","DOIUrl":"10.1007/s11864-024-01287-0","url":null,"abstract":"Opinion statement: Cardiac sarcomas are rare, aggressive malignancies originating from various cardiac cell types, presenting significant challenges in both diagnosis and treatment. This comprehensive review explores recent advancements in diagnosis and treatment of cardiac angiosarcoma, fibrosarcoma, leiomyosarcoma, and rhabdomyosarcoma. And we briefly discuss the exceedingly rare occurrence of cardiac osteosarcoma and present our perspectives on its treatment. Development of these tumors is influenced by genetic mutations, environmental factors, and chromosomal abnormalities, necessitating a multidisciplinary approach for accurate diagnosis and management. Advanced imaging techniques, biomarkers, and immunohistochemical analysis assist in confirming the diagnosis and guiding treatment decisions. Surgical resection, adjuvant therapies, and personalized treatment strategies based on genetic profiling offer promising avenues for improving patient outcomes. Emerging therapeutic approaches, such as targeted therapies and immunotherapies, have shown promising progress in recent years. Despite these advancements, the prognosis for patient with cardiac sarcomas remains poor, highlighting the urgent need for continued research to refine treatment methods and enhance long-term survival outcomes. Ongoing efforts and clinical trials are essential for advancing the management of these rare and aggressive tumors, ultimately improving quality of life for affected patients.","PeriodicalId":50600,"journal":{"name":"Current Treatment Options in Oncology","volume":" ","pages":"103-127"},"PeriodicalIF":3.8,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143069372","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Advances in the Pathogenesis, Diagnosis, Treatment, and Prognosis of Marginal Zone Lymphoma.

IF 3.8 2区医学

Current Treatment Options in Oncology Pub Date : 2025-02-01 DOI: 10.1007/s11864-025-01293-w

Qingyang Zhang, Wenzhe Yan, Heng Li, Hongling Peng

{"title":"Advances in the Pathogenesis, Diagnosis, Treatment, and Prognosis of Marginal Zone Lymphoma.","authors":"Qingyang Zhang, Wenzhe Yan, Heng Li, Hongling Peng","doi":"10.1007/s11864-025-01293-w","DOIUrl":"10.1007/s11864-025-01293-w","url":null,"abstract":"Opinion statement: The management of marginal zone lymphoma (MZL), an indolent B-cell non-Hodgkin lymphoma, requires a personalized and adaptive approach due to its clinical and prognostic heterogeneity. We believe treatment should emphasize a balanced strategy considering the subtype, disease burden, symptoms, and actionable genetic or environmental factors, such as infections or autoimmune diseases. For asymptomatic patients with low tumor burden or disseminated disease, a watch-and-wait approach remains appropriate, given MZL's indolent nature and the risks of overtreatment. Conversely, for symptomatic or high-burden cases, early intervention with chemoimmunotherapy is recommended for effective disease control. Surgery remains essential for both diagnosis and the treatment of localized disease. Incorporating molecular profiling and prognostic models, such as MZL-IPI and POD24, is crucial for decision-making and risk stratification. Testing for infectious agents like Helicobacter pylori or Hepatitis C virus should be standard practice, as eradication therapy offers a targeted, less toxic, and effective option in select patients. With ongoing advancements in understanding dysregulated signaling pathways and the tumor microenvironment, we anticipate novel targeted therapies and combination regimens will further improve outcomes. We advocate for molecular testing at diagnosis to identify actionable biomarkers, particularly for patients with refractory or relapsed disease. Finally, MZL management requires vigilant follow-up with adjustments based on evolving disease features. Treatment decisions should integrate patient preferences, clinical context, and the latest evidence to maximize survival while preserving quality of life.","PeriodicalId":50600,"journal":{"name":"Current Treatment Options in Oncology","volume":" ","pages":"142-155"},"PeriodicalIF":3.8,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143076294","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The Review of Modified Intersphincteric Resection in the Treatment of Ultra-Low Rectal Cancer.

IF 3.8 2区医学

Current Treatment Options in Oncology Pub Date : 2025-02-01 Epub Date: 2025-01-23 DOI: 10.1007/s11864-025-01291-y

Danni Li, Xi Xiong, Pan Diao, Jitao Hu, Wenbo Niu, Guiying Wang, Baokun Li

引用次数: 0

Candidate Biomarker of Response to Immunotherapy In Small Cell Lung Cancer. 小细胞肺癌免疫治疗应答的候选生物标志物。

IF 3.8 2区医学

Current Treatment Options in Oncology Pub Date : 2025-02-01 Epub Date: 2025-01-22 DOI: 10.1007/s11864-025-01292-x

Yili Shen, Zhicong Liu, Yi Chen, Xuefei Shi, Shunli Dong, Bin Wang

{"title":"Candidate Biomarker of Response to Immunotherapy In Small Cell Lung Cancer.","authors":"Yili Shen, Zhicong Liu, Yi Chen, Xuefei Shi, Shunli Dong, Bin Wang","doi":"10.1007/s11864-025-01292-x","DOIUrl":"10.1007/s11864-025-01292-x","url":null,"abstract":"Opinion statement: Small-cell lung cancer accounts for about 15% of lung cancers with an extremely poor prognosis. The incorporation of immunotherapy to platinum-based chemotherapy offers sustained overall survival benefits and become the standard for the first-line setting of extensive-stage small-cell lung cancer. However, only a limited number of patients derive prolonged benefits. Although novel immunomodulatory agents and combination strategies are currently under investigation, identifying patients who are likely to obtain clinical benefits from this therapeutic approach is urgently needed. The modest therapeutic response to immunotherapy can be explained by various mechanisms. Traditional biomarkers do not guide immunotherapeutic decision-making in small-cell lung cancer. Notably, recent progress in the understanding of the molecular typing of small-cell lung cancer based on multi-omics data might bring new sights. This review summarizes the potential biomarkers for small-cell lung cancer immunotherapy based on clinical trials and preclinical studies. Moreover, important constraints in identifying biomarkers for small-cell lung cancer treatment are discussed.","PeriodicalId":50600,"journal":{"name":"Current Treatment Options in Oncology","volume":" ","pages":"73-83"},"PeriodicalIF":3.8,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143015657","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Evolving Immunotherapy Strategies in Gastrointestinal Neuroendocrine Neoplasms.

IF 3.8 2区医学

Current Treatment Options in Oncology Pub Date : 2025-02-01 Epub Date: 2025-01-23 DOI: 10.1007/s11864-024-01283-4

Arielle Urman, Ian Schonman, Ana De Jesus-Acosta

{"title":"Evolving Immunotherapy Strategies in Gastrointestinal Neuroendocrine Neoplasms.","authors":"Arielle Urman, Ian Schonman, Ana De Jesus-Acosta","doi":"10.1007/s11864-024-01283-4","DOIUrl":"10.1007/s11864-024-01283-4","url":null,"abstract":"Opinion statement: Treatment for neuroendocrine neoplasms (NENs) is tailored to the tumor's site of origin, grade, and differentiation. NENs are categorized into two main types: well-differentiated neuroendocrine tumors (NETs), which tend to grow more slowly and are less aggressive, and poorly differentiated neuroendocrine carcinomas (NECs), which are highly aggressive and harder to treat. Treatment options for NETs range from somatostatin analogues and mTOR inhibitors to peptide receptor radionuclide therapy (PRRT) with Lutetium-177 dotatate. In cases where the disease progresses more rapidly, cytotoxic chemotherapy may also be considered. In contrast, chemotherapy plays a central role in treating NECs, often following protocols similar to those used for small cell lung cancer. Exciting progress is being made in the development of new therapies for NENs. Inspired by the success of immunotherapy in other cancers, clinical trials have begun to explore its potential in NENs. Early findings suggest that immune checkpoint inhibitors (ICIs) may offer benefits, especially in patients with higher-grade NETs and NECs. However, because NENs have an immunologically \"cold\" tumor microenvironment-meaning they are less likely to trigger an immune response-new strategies are needed to boost ICI efficacy. To overcome this challenge, researchers are exploring innovative approaches, such as combining dual ICIs or pairing ICIs with other therapeutic agents to make the tumors more responsive to immune attack. Moreover, there is growing enthusiasm for cutting-edge therapies designed to enhance the immune system's ability to recognize and destroy cancer cells. These include bispecific T cell engagers, chimeric antigen receptor T cells, tumor-infiltrating lymphocytes, oncolytic viruses, and cancer vaccines. While their effectiveness in NENs is still being studied, these approaches hold considerable promise, offering new hope for patients with this challenging and complex cancer type.","PeriodicalId":50600,"journal":{"name":"Current Treatment Options in Oncology","volume":" ","pages":"92-102"},"PeriodicalIF":3.8,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143025508","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Targets Selection for Precision Therapy of Relapsed/Refractory Multiple Myeloma: the Latest Advancements.

IF 3.8 2区医学

Current Treatment Options in Oncology Pub Date : 2025-02-01 Epub Date: 2025-01-31 DOI: 10.1007/s11864-025-01290-z

Zhen Wang, Yanqi Song, Honglei Guo, Yuting Yan, Lin Ma, Baoshan Liu

{"title":"Targets Selection for Precision Therapy of Relapsed/Refractory Multiple Myeloma: the Latest Advancements.","authors":"Zhen Wang, Yanqi Song, Honglei Guo, Yuting Yan, Lin Ma, Baoshan Liu","doi":"10.1007/s11864-025-01290-z","DOIUrl":"10.1007/s11864-025-01290-z","url":null,"abstract":"Opinion statement: According to the guidelines, the primary treatment for multiple myeloma is still based on drugs such as carfilzomib, lenalidomide, or daratumumab. However, patients with relapsed/refractory multiple myeloma (RRMM) may be insensitive or develop resistance to the above therapeutic medications. Thus, formulating standardized and rational treatment regimens for such patients remains an area for consideration. Multidrug combinations are available for the therapy of patients with relapsed/refractory multiple myeloma to improve their clinical outcome and prevent the occurrence of multidrug resistance. For instance, combination therapy with immunomodulators, proteasome inhibitors, and CD38 monoclonal antibodies. With the development of genomics and molecular diagnostic technologies, RRMM has entered the era of precision therapy. Targeted immunotherapeutic drugs such as monoclonal antibodies, bispecific antibodies, antibody-drug conjugates (ADCs), and chimeric antigen receptor-T (CAR-T) cells have shown promising clinical response rates and favorable safety profiles in several clinical and experimental studies. These cutting-edge medicinal treatments may provide new hope for a cure for RRMM. However, the choice of treatment regimen still needs to adhere to the principle of individualization. Generally, we recommend treatment with drugs of a new generation or novel mechanism of action for patients with RRMM who are first relapsed, such as next-generation proteasome inhibitors, next-generation immunomodulators, and CD38-based monoclonal antibody regimens. For multiple relapsed RRMM, we recommend choosing a combination regimen or participating in relevant clinical trials. Additionally, monoclonal antibodies have become the standard of care for patients with RRMM. With the introduction of CAR-T therapy, ADCs, and bispecific antibodies, RRMM patients are expected to achieve deep remissions and long-term survival again.","PeriodicalId":50600,"journal":{"name":"Current Treatment Options in Oncology","volume":" ","pages":"128-141"},"PeriodicalIF":3.8,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143069377","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A fishnet between nasopharyngeal carcinoma and resistance: the competing endogenous RNA network. 鼻咽癌与耐药之间的渔网：竞争的内源性RNA网络。

IF 3.8 2区医学

Current Treatment Options in Oncology Pub Date : 2025-01-01 Epub Date: 2025-01-15 DOI: 10.1007/s11864-024-01284-3

Mingtai Li, Tongtong Mo, Zisha Yang, Yunhong Yao, Yan Wang, Yi Zhao

引用次数: 0

A Review on Integrating Breast Cancer Clinical Data: A Unified Platform Perspective. 乳腺癌临床数据整合综述：统一平台视角。

IF 3.8 2区医学

Current Treatment Options in Oncology Pub Date : 2025-01-01 Epub Date: 2025-01-03 DOI: 10.1007/s11864-024-01285-2

Ram Mohan Ram Kumar, Suresh Joghee

{"title":"A Review on Integrating Breast Cancer Clinical Data: A Unified Platform Perspective.","authors":"Ram Mohan Ram Kumar, Suresh Joghee","doi":"10.1007/s11864-024-01285-2","DOIUrl":"10.1007/s11864-024-01285-2","url":null,"abstract":"Opinion statement: Integrating clinical datasets in breast cancer research emerges as a necessary tool for advancing our knowledge of the disease and enhancing patient outcomes. Synthesizing diverse datasets offers advantages, from facilitating evidence-based insights to enabling predictive analytics and precision medicine strategies. Crucially, effective integration of clinical datasets necessitates collaborative efforts, policy interventions, and technological advancements to elevate global standards of breast cancer care. This narrative review underscores the imperative and substantial benefits of dataset integration in advancing breast cancer research and optimizing patient management. First, integrating diverse datasets-encompassing patient demographics, tumor characteristics, treatment modalities, and clinical outcomes-can significantly enhance our understanding of the disease's complexities and treatment responses across diverse patient populations. Second, we suggest that regulatory approval processes should allow new treatments to be conditionally approved for patients who were not part of the initial trials. This approval would depend on evaluating how well these treatments perform in real-world situations before full approval is granted. Third, we emphasize the importance of incorporating high-quality real-world evidence into treatment guidelines to better inform patient counselling and optimize personalized treatment strategies.","PeriodicalId":50600,"journal":{"name":"Current Treatment Options in Oncology","volume":" ","pages":"1-13"},"PeriodicalIF":3.8,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142923912","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0